Artineh Hayrapetian
Papers
1
Total Citations
17
H-Index
1
About
Artineh Hayrapetian is a clinician-researcher whose work sits at the intersection of nuclear medicine and oncology, with a particular focus on advancing molecular imaging techniques for cancer staging and incidental findings. Her most cited work, published in *Clinical Nuclear Medicine* (2020), investigates the incidental detection of elastofibroma dorsi using both 68Ga-FAPI-46 and 18F-FDG PET/CT in a patient with esophageal cancer—a study that has garnered 17 citations and highlights her contribution to understanding fibroblast activation protein (FAP) imaging. This research, conducted under the prospective trial NCT04147494, demonstrates her role in refining PET/CT protocols to differentiate benign from malignant uptake, directly impacting surgical decision-making. Hayrapetian’s work bridges the gap between novel radiopharmaceuticals and real-world clinical application, offering insights into how dual-tracer imaging can reduce false positives in cancer staging. Her findings are particularly valuable for researchers and trainees in nuclear medicine and surgical oncology, as they underscore the importance of meticulous image interpretation in the era of targeted tracers. Through this study, she has established herself as a careful observer of incidental findings, contributing to safer, more accurate oncologic care.
Research Focus
Key Achievements
Top Papers
- 1